On Feb. 1, Novartis Pharmaceuticals Canada Inc. announced that the Nova Scotia government is funding Pluvicto injections for ...

When hormone therapy stops working, the cancer is said to be “castration resistant.” On average, it takes about two years for prostate cancer to become resistant to hormone therapy ...

Prostate cancer is one of the most prevalent cancers among men and poses a significant health concern, with its incidence on ...

A new drug, NXP800, shows promise in treating hormone therapy-resistant prostate cancer by targeting the Heat Shock Factor 1 (HSF1) pathway, which supports cancer cell growth.

2. Ovarian Cancer: Research indicates that a woman's chance of developing ovarian cancer may be influenced by hormonal ...

Hormone therapy is used to slow the progression of advanced prostate cancer, but cancers often develop resistance and continue to grow Research reveals that patients with higher levels of heat shock ...

In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research published in ...

One of the UK's leading radiotherapy experts, Professor Adrian Crellin, has been diagnosed with incurable cancer and ...

Today, on World Cancer Day, we come together to raise awareness, promote early detection and encourage prevention.

IT’S a disease that only affects old men. Wrong. You won’t die of it, you die with it. Wrong again! Prostate cancer is the most common cancer in England, overtaking breast cancer for the first ...

found NXP800 slowed the growth of prostate cancer cells, including those that had developed a resistance to the hormone therapy enzalutamide. Dr Adam Sharp, leader of the Translational ...